Please login to the form below

Not currently logged in
Email:
Password:

Patent loss

This page shows the latest Patent loss news and features for those working in and with pharma, biotech and healthcare.

Janssen’s Erleada improves survival in certain advanced prostate cancer patients

Janssen’s Erleada improves survival in certain advanced prostate cancer patients

Androgen inhibitor Erleada (apalutamide) is Janssen’s follow-up to its older, blockbuster prostate cancer drug Zytiga (abiraterone acetate), which has now been hit by the loss of patent protection and

Latest news

More from news
Approximately 1 fully matching, plus 153 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    Pfizer is coming off ten years of patent expiries, plus a pipeline that hasn’t yielded as many new products as hoped in that period, and that prompted Bourla to implement ... He has already taken some pretty seismic decisions, such as axing R&D in

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    There’s also some urgency for the transaction to go quickly and smoothly as AbbVie prepares for the loss of patent protection for $20bn immunology drug Humira (adalimumab) in the US ... AZ’s new growth phase comes after a six-year sales slump thanks

  • Deal Watch October 2018

    The termination comes as a consequence of patent infringement litigation which has placed a stay on the FDA’s approval of the biosimilar, Lusduna Nexvue, in the US. ... non‐biologic product post‐patent loss, highlighting the benefits of biologics

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    years for AZ to return to top-line growth after the patent loss of blockbuster brands such as Nexium and Crestor.

  • Pharma deals during February 2014 Pharma deals during February 2014

    been much analysis as to why Actavis paid as much as it did when Forest seemingly could have been bought much more cheaply, given the loss of patent protection on ... s best selling depression drug Lexapro and another patent cliff looming for Nameda, its

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics